Related Product Information
Note: To detach the Dynabeads from the isolated cells, use DETACHaBEAD® CD19 (not supplied).
Principle of Isolation
Dynabeads are mixed with the sample in a tube. The Dynabeads will bind to the target cells during a short incubation, and then the bead-bound cells are separated by a magnet.
- Positive isolation – discard the supernatant and use the bead-bound cells for downstream applications (e.g. molecular analysis or cell culture).
- Depletion – discard the bead-bound cells and use the remaining, untouched cells for any application.
Description of Materials
Dynabeads CD19 are uniform, superparamagnetic polystyrene beads (4.5 μm diameter) coated with a monoclonal antibody specific for the CD19 membrane antigen.
- 5 ml Dynabeads CD19 pan B 4 x 108beads/ml in phosphate buffered saline (PBS), pH 7.4, containing 0.1% bovine serum albumin (BSA) and 0.02% sodium azide (NaN3).
- This product can be used to process up to 5 x 109 cells.
Additional Materials Required
- Magnet (Dynal MPC™): See www.invitrogen.com/magnets-selection for magnet recommendations.
- Mixer allowing both tilting and rotation.
- Buffer 1: PBS (without Ca2+ and Mg2+) w/0.1% BSA and 2 mM EDTA, pH 7.4.
- Optional: DETACHaBEAD CD19 (Cat. no. 125.06D)
Dynabeads should be washed before use.
1. Resuspend the Dynabeads in the vial.
2. Transfer the desired volume of Dynabeads to a tube.
3. Add the same volume of Buffer 1, or at least 1 ml, and mix.
4. Place the tube in a magnet for 1 min and discard the supernatant.
5. Remove the tube from the magnet and resuspend the washed Dynabeads in the same volume of Buffer 1 as the initial volume of Dynabeads.
Cells can be directly isolated from any sample such as whole blood, bone marrow, MNC suspensions or tissue digests.
Please visit www.invitrogen.com/samplepreparation for a list of recommended sample preparation procedures.
Critical Steps for Cell Isolation
- Use a mixer that tilts and rotates the tubes to ensure Dynabeads do not settle at the bottom of the tube.
- When incubating Dynabeads and cells, the incubation temperature must be 2 - 8°C to reduce phagocytic activity and other metabolic processes.
- Never use less than 25 μl Dynabeads per ml cell sample and at least 4 Dynabeads per target cell.
Table 1: Volume of Dynabeads added per ml of cell sample. The volumes can be scaled up as required.
(e.g. 2.5 x 107 cells/ml)
Max 2.5 x 106 target cells/ml*
|1 ml ||1 ml|
|Volume of Dynabeads||25 μl||50 μl|
|Total no. of cells|
processed per product
|5 x 109 cells||2.5 x 109cells|
* If the concentration of target cells is increased, the volume of Dynabeads must be increased accordingly. Cell concentration can be up to 1 x 108 cells per ml.
- Add Dynabeads to the prepared sample according to table 1.
- Incubate for 20 min (positive isolation) or 30 min (depletion) at 2 - 8°C with gentle tilting and rotation.
- Place the tube in a magnet for 2 min.
- Depletion: Transfer the supernatant containing the unbound cells to a fresh tube for further experiments.
- Positive isolation: Discard the supernatant and gently wash the bead-bound cells 4 times, using the following procedure:
i) Add 1 ml Buffer 1 per 1 x 107Dynabeads.
ii) Place the tube in the magnet for 1 min and discard the supernatant.
- Resuspend the cells in buffer/medium for downstream application. For molecular studies, lyse cells while still attached to the beads and transfer supernatant to a new tube for protein or gene expression analysis.
Detachment of Dynabeads from Isolated Cells
Efficient detachment of Dynabeads CD19 from the positively isolated cells is achieved by using DETACHaBEAD® CD19 (Cat. no. 125.06D) – see protocol at www.invitrogen.com for details.
This product is stable until the expiry date stated on the label when stored unopened at 2-8°C. Store opened vials at 2-8°C and avoid bacterial contamination. Keep Dynabeads in liquid suspension during storage and all handling steps, as drying will result in reduced performance. Resuspend well before use.
Warnings And Limitations
This product is for research use only. Not intended for any animal or human therapeutic or diagnostic use unless otherwise stated. Follow appropriate laboratory guidelines. This product contains 0.02% sodium azide as a preservative, which is cytotoxic.
Avoid pipetting by mouth!
Sodium azide may react with lead and copper plumbing to form highly explosive metal azides. When disposing through plumbing drains, flush with large volumes of water to prevent azide build up. Certificate of Analysis (CoA) is available upon request. Material Safety Data Sheet (MSDS) is available at http://www.invitrogen.com.
- Baize S et al. (2004) Lassa virus infection of human dendritic cells and macrophages is productive but fails to activate cells. J. Immunol. 172: 2861-2869.
- Beckhove P et al. (2004) Specifically activated memory T cell subsets from cancer patients recognize and reject xenotransplanted autologous tumors. J. Clinical Investigation. 114:67-76.
- Døsen G et al. (2006) Wnt expression and canonical Wnt signalling in human bone marrow B lymphopoiesis. BMC Immunology, www.biomedcentral. com/1471-2172/7/13.
- Ellyard J et al. (2004) Antigenselected, immunoglobulin-secreting cells persist in human spleen and bone marrow. Blood 103: 3805- 3812.
- Ertesvag A et al. (2002) Retinoic acid stimulates the cell cycle machinery in normal T cells: involvement of retinoic acid receptor-mediated IL-2 secretion. J. Immunol. 169: 5555-5563.
- Gee K et al. (2007) IL-10 Regulation by HIV-Tat in Primary Human Monocytic Cells: Involvement of Calmodulin/Calmodulin-Dependent Protein Kinase-Activated p38 MAPK and Sp-1 and CREB-1 Transcription Factors. J. of Immunol. 178:798- 807.
- Gudmundsson KO et al. (2007) Gene Expression Analysis of Hematopoietic Progenitor Cells Identifies Dlg7 as a Potential Stem Cell Gene. Stem Cells 25:1498-1506.
- Holm AM et al. (2003) Impaired secretion of IL-10 by T cells from patients with common variable immunodeficiency-involvement of Protein Kinase A Type I. J. Immunol. 170: 5772-5777.
- Imadome K et al. (2003) CD40 ligand is a critical effector of Epstein- Barr virus in host cell survival and transformation. PNAS 100:7836-7840.
- Jain A et al. (2004) Specific NEMO mutations impair CD40-mediated cRel activation and B cell terminal differentiation. J. Clinical Investigation. 114:1593-1602.
- Mulder A et al. (2003) Identification, isolation and culture of HLAA2- specific B lymphocytes using MHC Class I tetramers. J. Immunol. 171: 6599-6603.
- Pellet C et al. (2006) Kaposi’s Sarcoma- Associated Herpesvirus Viremia is Associated with the Progression of Classic and Endemic Kaposi’s Sarcoma. J. Invest. Dermatol. 126:621-627.
- Rieder H et al. (2003) Cell lineage assignment of cytogenetic findings in acute lymphoblastic leukemia using combined immunomagnetic cell separation and chromosome preparation. Haematologica 88:1317-1320.
- Le Rond S et al. (2006) Evidence to Support the Role of HLA-G5 in Allograft Acceptance through Induction of Immunosuppressive/ Regulatory T Cells. J. Immunol. 176:3266-3276.
- Spender L et al. (2001) Direct and indirect regulation of cytokine and cell cycle proteins by EBNA-2 during Epstein-Barr virus infection. J. Virol. 75(8): 3537-3546.
- Westerberg L et al. (2005) Wiskott- Aldrich syndrome protein deficiency leads to reduced B cell adhesion, migration and homing, and a delayed humoral immune response. Blood 105:1144-1152.
- Yang H et al. (2003) The androgen receptor gene is preferentially hypermethylated in follicular non-Hodgkin’s lymphoma. Clin. Cancer Res. 9:4034-4042.
- Zhu Y et al. (2003) Type Two Hyper-IgM Syndrome caused by mutation in activation-induced cytidine deaminase. J. Med.Dent.Sci. 50: 41-46.